NL-OMON31009Not yet recruitingPhase 2
Sorafenib as adjuvant to radioiodine therapy in non-medullary thyroid carcinoma - Sorafenib in Non Medullary Thyroid Carcinoma
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 30
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •· Patients with non-medullary thyroid carcinoma
- •· The patients must have undergone total thyroidectomy
- •· Presence of metastases or inoperable recurrent disease, as proven by elevated serum thyroglobulin levels (Tg) in combination with radiological evidence for tumor.
- •· No or insufficient RaI uptake in tumor as proven by RaI scintigraphy, performed after prior RaI therapy.
Exclusion Criteria
- •· Pregnancy
- •· Other active malignancies
- •· Active kidney, liver or pancreatic disease or dysfunction
- •· Unstable angina pectoris or recent (<3 months) myocardial infarction.
- •· Coagulopathy
Investigators
Similar Trials
Active, not recruiting
Phase 1
Sorafenib as adjuvant to radioiodine therapy in non-medullary thyroid carcinomaEUCTR2007-002365-13-NLBayer B.V.
Completed
Phase 2
Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid CarcinomaThyroid CancerNCT00887107Leiden University Medical Center32
Completed
Not Applicable
Study of sorafenib and radiation therapy for advanced hepatocellular carcinoma with portal vein thrombosisadvanced hepatocellular carcinomaJPRN-UMIN000008184Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine6
Completed
Phase 1
Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body WallSoft Tissue SarcomaNCT00864032University of California, Davis8
Active, not recruiting
Not Applicable
Sorafenib in the first line treatment of advanced hepatocellular carcinoma with ChildPugh liver function class B. Multicentre phase 3 randomized trial - BOOSTadvanced hepatocellular carcinoma with ChildPugh liver function class BMedDRA version: 9.1Level: LLTClassification code 10024720EUCTR2009-013870-42-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE